Methods of treating at least one condition associated with envenomation, pharmaceutical compositions, and kits comprising a first compound having formula (I): and a second compound chosen from N-acetyl-L-cysteine, sodium aurothiomalate, silibinin, sodium copper chlorophyllin, and pharmaceutically acceptable salts and solvates thereof.

##STR00001##

Methods of treating at least one condition associated with envenomation, pharmaceutical compositions, and kits comprising a first compound having formula (I): and a second compound chosen from N-acetyl-L-cysteine, sodium aurothiomalate, silibinin, sodium copper chlorophyllin, and pharmaceutically acceptable salts and solvates thereof.

##STR00001##

Methods of treating at least one condition associated with envenomation, pharmaceutical compositions, and kits comprising a first compound having formula (I): and a second compound chosen from N-acetyl-L-cysteine, sodium aurothiomalate, silibinin, sodium copper chlorophyllin, and pharmaceutically acceptable salts and solvates thereof.

##STR00001##

The present invention relates to a microelement organic O-chelate or N-chelate complex compound, for the inhibition of facultative pathogenic bacteria. The present invention further relates to a composition, feed additive or feed comprising the compounds, as well as methods for the preparation thereof, and for the use thereof in animal stock farming.

The present invention relates to a microelement organic O-chelate or N-chelate complex compound, for the inhibition of facultative pathogenic bacteria. The present invention further relates to a composition, feed additive or feed comprising the compounds, as well as methods for the preparation thereof, and for the use thereof in animal stock farming.

A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

Provided herein are formulations effective for and methods of treating or preventing a neurodegenerative disorder in a subject in need thereof that can include administering an amount of an aPKC inhibitor to a subject in need thereof.

The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.

The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.